Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors

Frontiers in Veterinary Science - Switzerland
doi 10.3389/fvets.2019.00106
Full Text
Abstract

Available in full text

Categories
Veterinary
Date
Authors
Publisher

Frontiers Media SA

Related search

Optimising Intratumoral Treatment of Head and Neck Squamous Cell Carcinoma Models With the Diterpene Ester Tigilanol Tiglate

Investigational New Drugs
OncologyPharmacology
2018English

Canine Mast Cell Tumors: A Comparison of Staining Techniques

Journal of Veterinary Diagnostic Investigation
Veterinary
1994English

Evaluation of the Kinase Domain of C-Kit in Canine Cutaneous Mast Cell Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Immunohistochemical and Clinical Evaluation of P53 in Canine Cutaneous Mast Cell Tumors

Veterinary Pathology
Veterinary
2000English

Variation Among Pathologists in Histologic Grading of Canine Cutaneous Mast Cell Tumors

Journal of Veterinary Diagnostic Investigation
Veterinary
2005English

Nanog Expression and Proliferation Indices in Canine Cutaneous Mast Cell Tumors

Veterinary Pathology
Veterinary
2018English

The Phosphoinositide 3-Kinase Pathway Is Crucial for the Growth of Canine Mast Cell Tumors

Journal of Veterinary Medical Science
Veterinary
2013English

Detection of C-Kit Mutations in Canine Mast Cell Tumors Using Fluorescent Polyacrylamide Gel Electrophoresis

Journal of Veterinary Diagnostic Investigation
Veterinary
2004English

Neuroendocrine (Merkel) Cell Tumors of the Canine Oral Cavity

Veterinary Pathology
Veterinary
1987English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy